MedPath

se of Venlafaxine in the treatment of adult attention deficit hyperactivity disorder

Phase 2
Conditions
Adult ADHD (Attention-deficit hyperactivity disorder ).
Hyperkinetic disorders
Registration Number
IRCT138808122660N1
Lead Sponsor
Vice Chancellor for Research of Tabriz Univercity of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

1. Age between 18-45 year 2. Having Adult attention deficit hyperactivity disorder (ADHD) according to the judgment of two psychiatrists 3. Confirm of ADHD symptoms at childhood period.
Exclusion criteria: 1. Evidence of mental retardation ( IQ<70 based on clinical judgment ) 2. Other psychiatric comorbidity 3. Any significant chronic medical condition, including organic brain disorder and seizure 4. Current abuse or dependence on substance within 6 months 5. Pregnant and lactating women . 6. use any psychiatirc drugs in recent two weeks

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in Attention-deficit symptoms. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the self-report Conner's questionnaire.;Improvement in impulsivity. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the Self-report Conner's questionnaire.;Improvement in hyperactivity symptoms. Timepoint: weeks 2, 4 and 6. Method of measurement: According to the Self-report Conner's questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath